| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | - | 289 | 0 | 0 |
| Total Income - EUR | - | - | - | - | - | - | - | 10.380 | 11.869 | 167.469 |
| Total Expenses - EUR | - | - | - | - | - | - | - | 677.741 | 52.846 | 167.069 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | - | -667.361 | -40.977 | 400 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | - | -667.364 | -40.977 | 400 |
| Employees | - | - | - | - | - | - | - | 3 | 1 | 0 |
Check the financial reports for the company - Pharmadrug S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | - | 241 | 76 | 0 |
| Current Assets | - | - | - | - | - | - | - | 343.198 | 294.404 | 292.887 |
| Inventories | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | - | - | 53.574 | 17.999 | 167.788 |
| Cash | - | - | - | - | - | - | - | 289.625 | 229.614 | 125.099 |
| Shareholders Funds | - | - | - | - | - | - | - | 335.911 | 293.915 | 292.673 |
| Social Capital | - | - | - | - | - | - | - | 52 | 52 | 51 |
| Debts | - | - | - | - | - | - | - | 7.560 | 564 | 214 |
| Income in Advance | - | - | - | - | - | - | - | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2120 - 2120" | |||||||||
| CAEN Financial Year |
2120
|
|||||||||
Comments - Pharmadrug S.r.l.